<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000631</url>
  </required_header>
  <id_info>
    <org_study_id>AVEG 002B</org_study_id>
    <secondary_id>10539</secondary_id>
    <nct_id>NCT00000631</nct_id>
  </id_info>
  <brief_title>A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)</brief_title>
  <official_title>A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Primary: To determine whether additional boosting with soluble recombinant gp160 vaccine&#xD;
      (VaxSyn) after priming with a vaccinia-HIV envelope recombinant (HIVAC-1e) provides a&#xD;
      significant advantage in the degree and duration of immunogenicity. Secondary: To learn more&#xD;
      about the safety of the combination use of the two HIV envelope vaccines in the study (VaxSyn&#xD;
      and HIVAC-1e).&#xD;
&#xD;
      Recent Phase I trials conducted at the AIDS Vaccine Units have shown that antibodies have&#xD;
      persisted in most recipients for 6 months after boosting, and responses seem significantly&#xD;
      higher and more persistent than responses achieved by just two doses of soluble protein&#xD;
      vaccine alone or two doses of HIVAC-1e alone. This study tests in a previously recruited&#xD;
      cohort of volunteers whether additional boosting with soluble recombinant gp160 results in&#xD;
      increased immunogenicity of longer duration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent Phase I trials conducted at the AIDS Vaccine Units have shown that antibodies have&#xD;
      persisted in most recipients for 6 months after boosting, and responses seem significantly&#xD;
      higher and more persistent than responses achieved by just two doses of soluble protein&#xD;
      vaccine alone or two doses of HIVAC-1e alone. This study tests in a previously recruited&#xD;
      cohort of volunteers whether additional boosting with soluble recombinant gp160 results in&#xD;
      increased immunogenicity of longer duration.&#xD;
&#xD;
      Twelve volunteers who have previously received two doses of HIVAC-1e (or DryVax) and two&#xD;
      doses of gp160 receive an additional boost of gp160 at 12-20 months after the last boost and&#xD;
      an additional dose of HIVAC-1e at least 9 months after the final gp160 boost.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">December 1992</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>13</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIVAC-1e</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp160 Vaccine (MicroGeneSys)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Normal history and physical exam.&#xD;
&#xD;
          -  Negative ELISA for HIV.&#xD;
&#xD;
          -  Negative HIV p24 antigen test.&#xD;
&#xD;
          -  Normal urinalysis.&#xD;
&#xD;
        Prior Medication: Required:&#xD;
&#xD;
          -  Two prior doses of HIVAC-1e (or DryVax) and two prior doses of gp160 vaccine.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms and conditions are excluded:&#xD;
&#xD;
          -  Risk factors for HIV infection including active intravenous drug use and more than 2&#xD;
             sexual partners.&#xD;
&#xD;
          -  History of immunodeficiency or chronic illness.&#xD;
&#xD;
          -  Hypersensitivity to insects.&#xD;
&#xD;
          -  Medical or psychiatric condition that makes it unlikely the patient will comply with&#xD;
             the protocol.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of immunodeficiency or chronic illness.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Immunosuppressive medications.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Blood or blood product transfusion within the past 6 months.&#xD;
&#xD;
        Risk Behavior: Excluded:&#xD;
&#xD;
          -  Intravenous drug use.&#xD;
&#xD;
          -  More than 2 sexual partners.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corey L</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital &amp; Medical Center / Seattle ACTU</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>981050371</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McElrath MJ, Corey L, Greenberg PD. Evaluation of cytotoxic T cell responses to candidate HIV-1 vaccines in HIV-1-uninfected individuals. AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S69-72.</citation>
    <PMID>7865336</PMID>
  </reference>
  <reference>
    <citation>Kent SJ, Greenberg PD, Hoffman MC, Akridge RE, McElrath MJ. Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection: potential mechanism of vaccine failure. J Immunol. 1997 Jan 15;158(2):807-15.</citation>
    <PMID>8992998</PMID>
  </reference>
  <reference>
    <citation>Mosier DE, Gulizia RJ, MacIsaac PD, Corey L, Greenberg PD. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2443-7. doi: 10.1073/pnas.90.6.2443.</citation>
    <PMID>8460155</PMID>
  </reference>
  <reference>
    <citation>McElrath J, Peterson E, Dragavon J, Berger D, Hoffman M, Klucking S, Greenberg P, Corey L. Combination prime-boost approach to HIV vaccination in seronegative individuals: enhanced immunity with additional subunit gp160 protein boosting. Int Conf AIDS. 1992 Jul 19-24;8(1):Mo9 (abstract no MoB 0027)</citation>
  </reference>
  <reference>
    <citation>McElrath MJ, Rabin M, Hoffman M, Klucking S, Garcia JV, Greenberg PD. Evaluation of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte responses utilizing B-lymphoblastoid cell lines transduced with the CD4 gene and infected with HIV-1. J Virol. 1994 Aug;68(8):5074-83. doi: 10.1128/JVI.68.8.5074-5083.1994.</citation>
    <PMID>8035507</PMID>
  </reference>
  <reference>
    <citation>McElrath MJ, Corey L, Greenberg PD, Matthews TJ, Montefiori DC, Rowen L, Hood L, Mullins JI. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3972-7. doi: 10.1073/pnas.93.9.3972.</citation>
    <PMID>8633000</PMID>
  </reference>
  <reference>
    <citation>Cooney EL, McElrath MJ, Corey L, Hu SL, Collier AC, Arditti D, Hoffman M, Coombs RW, Smith GE, Greenberg PD. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1882-6. doi: 10.1073/pnas.90.5.1882.</citation>
    <PMID>8446603</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccines, Synthetic</keyword>
  <keyword>Vaccinia Virus</keyword>
  <keyword>Viral Envelope Proteins</keyword>
  <keyword>Viral Vaccines</keyword>
  <keyword>AIDS Vaccines</keyword>
  <keyword>HIV Seronegativity</keyword>
  <keyword>HIV Preventive Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccinia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

